Non-Hodgkin Lymphoma News

Curcumin and non-Hodgkin’s lymphoma: Benefits and risks - Medical News Today

Curcumin and non-Hodgkin’s lymphoma: Benefits and risks Medical News Today

Diffuse Large B-cell Lymphoma of the Breast Presenting 40 Years After Breast-Conserving Therapy: A Case Report - Cureus

Diffuse Large B-cell Lymphoma of the Breast Presenting 40 Years After Breast-Conserving Therapy: A Case Report Cureus

Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story - Oncodaily

Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story Oncodaily

Cema-Cel Improves MRD Clearance as First-Line Consolidation in Large B-Cell Lymphoma - OncLive

Cema-Cel Improves MRD Clearance as First-Line Consolidation in Large B-Cell Lymphoma OncLive

Non-Hodgkin lymphoma survivor thankful for clinical trial - UT MD Anderson

Non-Hodgkin lymphoma survivor thankful for clinical trial UT MD Anderson

New long-term analysis suggests follicular lymphoma can be cured - Fred Hutchinson Cancer Center

New long-term analysis suggests follicular lymphoma can be cured Fred Hutchinson Cancer Center

Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients - statnews.com

Allogene Therapeutics’ CAR-T treatment eliminates residual cancer cells in B-cell lymphoma patients statnews.com

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch

Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete - Nature

Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma | Signal Transduction and Targete Nature

Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma - Targeted Oncology

Axi-Cel Shows Durable Responses, Curative Hope in Non-Hodgkin Lymphoma Targeted Oncology

Miami F Marcus Allen has non-Hodgkin lymphoma, out for season - ESPN

Miami F Marcus Allen has non-Hodgkin lymphoma, out for season ESPN

Transformation of Classical Hodgkin Lymphoma Into Non-Hodgkin Lymphoma: Three Case Reports From the West Bank - Wiley Online Library

Transformation of Classical Hodgkin Lymphoma Into Non-Hodgkin Lymphoma: Three Case Reports From the West Bank Wiley Online Library

A Rare Case of Non-Hodgkin Lymphoma of the Tracheobronchial Tree - Cureus

A Rare Case of Non-Hodgkin Lymphoma of the Tracheobronchial Tree Cureus

Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin - UT MD Anderson

Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about UT MD Anderson coming to Austin UT MD Anderson

Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial - Nature

Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial Nature

T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma - Targeted Oncology

T-Cell Therapy EB103 Demonstrates Safety in B-Cell Non-Hodgkin Lymphoma Targeted Oncology

Breast Mass as an Atypical Presentation of Non-Hodgkin Lymphoma - Cureus

Breast Mass as an Atypical Presentation of Non-Hodgkin Lymphoma Cureus

Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription - Nature

Hepatitis virus-associated B cell non-Hodgkin’s lymphoma involves dysregulated epigenetic and RNA-mediated regulatory gene expression and altered snoRNA transcription Nature

A Retrospective Analysis of the Clinicopathological Spectrum and Survival Outcome of Non-Hodgkin Lymphoma From a Tertiary Care Hospital in Saudi Arabia - Cureus

A Retrospective Analysis of the Clinicopathological Spectrum and Survival Outcome of Non-Hodgkin Lymphoma From a Tertiary Care Hospital in Saudi Arabia Cureus

Primary Non-Hodgkin Lymphoma of the Urinary Bladder in the Paediatric Age Group: A Report of a Rare Case - Cureus

Primary Non-Hodgkin Lymphoma of the Urinary Bladder in the Paediatric Age Group: A Report of a Rare Case Cureus

Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up of ZUMA-5 - The ASCO Post

Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-up of ZUMA-5 The ASCO Post

Non-Hodgkin lymphoma and HIV - Aidsmap

Non-Hodgkin lymphoma and HIV Aidsmap

Non-Hodgkin lymphoma survival rate: Outlook and more - Medical News Today

Non-Hodgkin lymphoma survival rate: Outlook and more Medical News Today

Diffuse Large B-Cell Lymphoma Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com

Diffuse Large B-Cell Lymphoma Clinical Trial Pipeline Gains Momentum: 70+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight Barchart.com

FDA Approves CAR-T Therapy for Marginal Zone Lymphoma - Oncology News Central

FDA Approves CAR-T Therapy for Marginal Zone Lymphoma Oncology News Central

Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation - Frontiers

Case Report: A case of jejunal T-cell non-Hodgkin lymphoma with secondary bone involvement presenting as gastrointestinal perforation Frontiers

Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma - The ASCO Post

Lymphocyte Kinetics After CAR T-Cell Infusion May Predict Survival Outcomes in Non-Hodgkin Lymphoma The ASCO Post

Dave Coulier Reveals New Cancer Diagnosis Months After Beating Non-Hodgkin Lymphoma - People.com

Dave Coulier Reveals New Cancer Diagnosis Months After Beating Non-Hodgkin Lymphoma People.com

New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy - UT MD Anderson

New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy UT MD Anderson

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma - Nature

Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma Nature

Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report - Frontiers

Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report Frontiers

Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy - Cureus

Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy Cureus